For decades, the pharmaceutical industry’s approach to mental health was a playbook of conservative, incremental innovation. The market was saturated with me-too drugs — slight variations on existing antidepressants and antipsychotics that offered predictable, modest returns. For investors, it was a safe bet. For patients suffering from the most severe forms of mental illness, it…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we learn AbbVie has ended its partnership with Calico, the FDA outlines how bespoke gene-editing treatments can make it through the regulatory pipeline, and more. The need-to-know this morning Day One Pharmaceuticals…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got big FDA news to get into today — let’s get straight into it. FDA names Richard Pazdur as top drug regulator The FDA yesterday said it has chosen Richard Pazdur, its…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, we just had our first snow of the season in Chicago, I just ordered a pie for Thanksgiving, and I’m still in denial that the year is almost ending. Onto the news…
Mergers and acquisitions are a spectator sport. You couldn’t hope for a better match to watch than the competition between Pfizer and Novo Nordisk over Metsera, a rollup of several experimental weight loss drugs founded three years ago. It had political intrigue, Big Pharma gamesmanship, and suspense, until Pfizer triumphed with a $10 billion offer….
Biotech is booming in China, and that’s no accident. While the most closely tracked U.S. index of biotech stocks is up more than 20% this year, Chinese biotech stocks are doing even better, staging a dazzling market rebound. The Hang Seng Biotech Index, which tracks the 30 largest biotech firms in Hong Kong, has climbed…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning, morning. Today, we have a trio of interesting studies on cholesterol reduction from the American Heart Association’s meeting in New Orleans. Also, Pfizer wins the Metsera deal with $10 billion, and we look…
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Morning! Lots in biotech today…. New priority review vouchers from the FDA, Mark Cuban rolls out a biosimilar deal, and a patient death is reported in Intellia’s CRISPR trial. Trump’s priority review vouchers…
WASHINGTON — The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s National Priority Voucher,” a ticket to speedier reviews of drug candidates aligned with U.S. priorities. The announcement came as the Trump administration unveiled agreements with Eli Lilly and Novo Nordisk to reduce the prices of popular weight…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Join us later today for a virtual event with STAT’s Jason Mast and Damian Garde about the past and future of Moderna — once one of biotech’s most secretive startups and now, well,…